Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 10:18 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 433–456 of 1,418 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Fluid administration Clear all
Terminated Not applicable Interventional

Safety and Treatment of Cryoinsufflation in Treatment of Hidradenitis Suppurativa

NCT05830149
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Cryoinsufflation, Deroofing
Other
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 30, 2024 · Synced Nov 9, 2026, 10:18 PM EST
Completed Not applicable Interventional Results available

Evaluation of the Candela 1064nm:Nd:YAG Laser for Skin Tightening

NCT00585715
View directory record Official record
Conditions
Localized Lipodystrophy
Interventions
1064 nm Nd:YAG laser
Device
Lead sponsor
University of California, Irvine
Other
Eligibility
40 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
2
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Oct 21, 2022 · Synced Nov 9, 2026, 10:18 PM EST
Terminated Phase 1 Interventional Results available

A Dose-escalation and Safety & Efficacy Study of AXO-AAV-GM2 in Tay-Sachs or Sandhoff Disease

NCT04669535
View directory record Official record
Conditions
Tay-Sachs Disease, Sandhoff Disease
Interventions
AXO-AAV-GM2 Starting Dose, AXO-AAV-GM2 Low Dose, AXO-AAV-GM2 Middle Dose, AXO-AAV-GM2 High Dose
Biological
Lead sponsor
Terence Flotte
Other
Eligibility
6 Months to 12 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
2
States / cities
Boston, Massachusetts • Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 2, 2025 · Synced Nov 9, 2026, 10:18 PM EST
Terminated Phase 3 Interventional

Management of Hyponatremia in Preterm Infants on Diuretics

NCT00156572
View directory record Official record
Conditions
Bronchopulmonary Dysplasia, Hyponatremia on Diuretics
Interventions
Sodium supplementation, Fluid restriction
Procedure
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
4 Weeks to 6 Months
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 27, 2007 · Synced Nov 9, 2026, 10:18 PM EST
Completed No phase listed Observational Accepts healthy volunteers

Craniosacral Therapy for Concussion Symptoms

NCT04820192
View directory record Official record
Conditions
Post-Concussion Syndrome
Interventions
Craniosacral Therapy
Other
Lead sponsor
Special Therapies, Inc.
Other
Eligibility
14 Years to 90 Years
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Waukesha, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 29, 2021 · Synced Nov 9, 2026, 10:18 PM EST
Completed Phase 1Phase 2 Interventional

Study of ACY-1215 Alone and in Combination With Bortezomib and Dexamethasone in Multiple Myeloma

NCT01323751
View directory record Official record
Conditions
Multiple Myeloma
Interventions
ACY-1215
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
6
States / cities
Atlanta, Georgia • Boston, Massachusetts • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2017 · Synced Nov 9, 2026, 10:18 PM EST
Completed Not applicable Interventional

MINDFUL-OBOT: Effect of Mindfulness on Opioid Use and Anxiety During Primary Care Buprenorphine Treatment

NCT03798431
View directory record Official record
Conditions
Opioid-use Disorder, Anxiety, Depression, Stress Related Disorder
Interventions
M-ROCC
Behavioral
Lead sponsor
Cambridge Health Alliance
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Somerville, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 14, 2025 · Synced Nov 9, 2026, 10:18 PM EST
Completed No phase listed Observational Accepts healthy volunteers

Mucosal Impedance Balloon in Diagnosis and Treatment of Eosinophilic Esophagitis (EoE)

NCT02995395
View directory record Official record
Conditions
Eosinophilic Esophagitis, Healthy
Interventions
Mucosal Impedance Balloon catheter
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 90 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 3, 2021 · Synced Nov 9, 2026, 10:18 PM EST
Completed No phase listed Observational

Octagam 5% Versus Comparator Post Marketing Trial

NCT01859754
View directory record Official record
Conditions
Primary Immune Deficiency Disorder
Interventions
Octagam 5%, Other marketed IVIG product
Biological
Lead sponsor
Octapharma
Industry
Eligibility
18 Years and older
Enrollment
623 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
27
States / cities
Granada Hills, California • Irvine, California • Los Angeles, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2019 · Synced Nov 9, 2026, 10:18 PM EST
Terminated Phase 3 Interventional Results available

Surgical Idiopathic Intracranial Hypertension Treatment Trial

NCT03501966
View directory record Official record
Conditions
Idiopathic Intracranial Hypertension
Interventions
Acetazolamide, Optic Nerve Sheath Fenestration, Ventriculoperitoneal CSF Shunting
Drug · Procedure
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
18 Years to 63 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
33
States / cities
Los Angeles, California • Palo Alto, California • Aurora, Colorado + 26 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2022 · Synced Nov 9, 2026, 10:18 PM EST
Withdrawn Not applicable Interventional

Impact of GDT in Robot-assisted Laparoscopic Urological Surgery for Low to Moderate Risk Patients

NCT03213574
View directory record Official record
Conditions
Vascular Hypotension, Hypovolemia, Hypervolemia
Interventions
Control Group, Treatment Group
Other
Lead sponsor
Loma Linda University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Loma Linda, California
Source: ClinicalTrials.gov public record
Updated Apr 5, 2018 · Synced Nov 9, 2026, 10:18 PM EST
Terminated Not applicable Interventional

EMS Prehospital Blood Culture Collection and Antibiotic Administration: A Two-Phase Pilot Project to Reduce Mortality in Patients With Severe Sepsis and Septic Shock

NCT04134624
View directory record Official record
Conditions
Sepsis, Sepsis, Severe, Septic Shock
Interventions
Sepsis care bundle
Other
Lead sponsor
HealthPartners Institute
Other
Eligibility
18 Years to 100 Years
Enrollment
215 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Stillwater, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 22, 2021 · Synced Nov 9, 2026, 10:18 PM EST
Completed No phase listed Observational Accepts healthy volunteers

Infertility Markers in Serum, Urine, and Follicular Fluid

NCT00194220
View directory record Official record
Conditions
Infertility
Interventions
Not listed
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
1,235 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 30, 2015 · Synced Nov 9, 2026, 10:18 PM EST
Terminated Phase 4 Interventional

Patiromer Utility as an Adjunct Treatment in Patients Needing Urgent Hyperkalemia Management

NCT04443608
View directory record Official record
Conditions
Hyperkalemia
Interventions
Patiromer Powder for Oral Suspension [Veltassa], Placebo
Drug
Lead sponsor
Comprehensive Research Associates
Industry
Eligibility
18 Years and older
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
19
States / cities
Stanford, California • New Haven, Connecticut • Newark, Delaware + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2023 · Synced Nov 9, 2026, 10:18 PM EST
Recruiting No phase listed Observational

Biomarkers for Risk Stratification in Lung Cancer

NCT03774758
View directory record Official record
Conditions
Nodule Solitary Pulmonary, Non-small Cell Lung Cancer
Interventions
Guardant Health ct-DNA LUNAR assay
Diagnostic Test
Lead sponsor
University of California, San Francisco
Other
Eligibility
40 Years and older
Enrollment
1,440 participants
Timeline
2017 – 2030
U.S. locations
3
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Nov 9, 2026, 10:18 PM EST
Completed No phase listed Observational Accepts healthy volunteers

Changes in Insulin Sensitivity After Weight Loss

NCT00627484
View directory record Official record
Conditions
Obesity, Type 2 Diabetes Mellitus, Insulin Resistance
Interventions
Gastric bypass, Gastric banding, Sleeve gastrectomy, Very low calorie diet
Procedure · Behavioral
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 75 Years
Enrollment
119 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 19, 2019 · Synced Nov 9, 2026, 10:18 PM EST
Completed Not applicable Interventional Results available

Middle Meningeal Artery Embolization for the Treatment of Subdural Hematomas With TRUFILL® n-BCA

NCT04816591
View directory record Official record
Conditions
Chronic Subdural Hematoma
Interventions
Experimental: Interventional Cohort: TRUFILL n-Butyl Cyanoacrylate (n-BCA) Liquid Embolic System, Standard of Care Surgery, Experimental: Interventional Cohort: TRUFILL n-BCA Liquid Embolic System, Standard of Care Medical Management
Device · Other
Lead sponsor
Cerenovus, Part of DePuy Synthes Products, Inc.
Industry
Eligibility
18 Years to 90 Years
Enrollment
376 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
31
States / cities
Birmingham, Alabama • Tucson, Arizona • Walnut Creek, California + 28 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2026 · Synced Nov 9, 2026, 10:18 PM EST
Withdrawn Not applicable Interventional Accepts healthy volunteers

Randomized Controlled Study Comparing Colon Evaluation With The Pure-Vu System To A Standard Colonoscopy In Patients Who Are High Risk For Inadequate Bowel Preparation

NCT04285008
View directory record Official record
Conditions
Gastrointestinal Disease, Colorectal Cancer
Interventions
Pure-Vu System
Device
Lead sponsor
Motus GI Medical Technologies Ltd
Industry
Eligibility
22 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 25, 2020 · Synced Nov 9, 2026, 10:18 PM EST
Active, not recruiting Phase 3 Interventional

Trial of Dichloroacetate in Pyruvate Dehydrogenase Complex Deficiency:

NCT02616484
View directory record Official record
Conditions
Pyruvate Dehydrogenase Complex Deficiency
Interventions
Dichloroacetate (DCA), Placebo, Genotype
Drug · Other · Genetic
Lead sponsor
Saol Therapeutics Inc
Industry
Eligibility
6 Months to 17 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
10
States / cities
Orange, California • Stanford, California • Washington D.C., District of Columbia + 7 more
Source: ClinicalTrials.gov public record
Updated May 4, 2025 · Synced Nov 9, 2026, 10:18 PM EST
Completed Early Phase 1 Interventional

Dose Adjusted EPOCH-R, to Treat Mature B Cell Malignancies

NCT01760226
View directory record Official record
Conditions
Diffuse Large B Cell Lymphoma, Post Transplant Lymphoproliferative Disorder, Primary Mediastinal (Thymic) Large B-cell Lymphoma
Interventions
DA-EPOCH-R for DLBCL, PTLD, AND PMBCL, Methotrexate, Etoposide, Doxorubicin, Vincristine, Rituximab, Cyclophosphamide, Prednisone, G-CSF
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
Up to 30 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Nov 9, 2026, 10:18 PM EST
Completed Phase 1 Interventional

A Safety Study of Rituximab Plus MTX Injected Into the Cerebrospinal Fluid in the Treatment of Brain Lymphoma

NCT00221325
View directory record Official record
Conditions
Central Nervous System Lymphoma, Intraocular Lymphoma
Interventions
Intraventricular Rituximab Plus MTX
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
4
States / cities
San Francisco, California • Boston, Massachusetts • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2015 · Synced Nov 9, 2026, 10:18 PM EST
Completed Phase 1 Interventional

Intraperitoneal Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Cancer of the Peritoneal Cavity

NCT00825201
View directory record Official record
Conditions
Ovarian Cancer, Peritoneal Cavity Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
paclitaxel albumin-stabilized nanoparticle formulation, liquid chromatography, mass spectrometry, pharmacological study, laboratory biomarker analysis
Drug · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
19 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
2
States / cities
Duarte, California • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Nov 9, 2026, 10:18 PM EST
Completed Not applicable Interventional Results available

Fluid Management in Transient Tachypnea of the Newborn

NCT01225029
View directory record Official record
Conditions
Transient Tachypnea of the Newborn
Interventions
Amount of total fluids
Other
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
Up to 24 Hours
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 28, 2013 · Synced Nov 9, 2026, 10:18 PM EST
Completed Phase 2 Interventional Results available

Vaccine Responses in Tralokinumab-Treated Atopic Dermatitis - ECZTRA 5 (ECZema TRAlokinumab Trial No. 5)

NCT03562377
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Tralokinumab, Placebo, Tdap vaccine, Meningococcal vaccine
Drug · Biological
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years to 54 Years
Enrollment
215 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
39
States / cities
Fort Smith, Arkansas • Bakersfield, California • Beverly Hills, California + 33 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2025 · Synced Nov 9, 2026, 10:18 PM EST